Many investigators in different parts of the world have determined their own starting dose for capecitabine, usually based on their experience of toxic events within the population of patients ...

Market research from the manufacturers of capecitabine indicates that the clinical community has voted with its empirical feet—it is relatively rare for US-based oncologists to prescribe the ...